logo
Holding paper receipts for just 10 seconds can pose health risks, researchers warn

Holding paper receipts for just 10 seconds can pose health risks, researchers warn

Yahoo24-04-2025
Health researchers are sounding the alarm about an endocrine disruptor commonly found in paper receipts – and they say it doesn't take long for your hands to absorb the chemical.
In an Apr. 14 statement, the Center for Environmental Health (CEH) announced a notice of violation for 32 retailers that allegedly had high levels of Bisphenol S (BPS) in their receipts.
In the official notice of violation on April 11, the companies named dozens of national corporations.
Men's Multivitamins Recalled Due To Undeclared Allergen: Fda
The organization described Bisphenol S (BPS) as the "lesser-known but harmful chemical cousin to BPA in receipt paper," and described the organic compound as "hormone-disrupting."
"BPS, like [Bisphenol A] … mimics estrogen and can disrupt the normal functioning of the body, including metabolism, growth and development, and reproduction," the statement said.
Read On The Fox News App
"Studies show that BPS can be absorbed through skin when handling receipt paper – even for short periods."
This Odd Dental Habit Could Spark Heart Health Risks, Experts Warn
The statement claimed that holding a BPS-laced receipt for just 10 seconds could have serious health consequences.
"Based on these studies and testing by an independent lab, the concentrations were so high that touching only one receipt with BPS for 10 seconds resulted in exposure above the safe harbor level, which requires a clear and reasonable warning to consumers," CEH Science Lead Mihir Vohra said in the press release.
CEH stated that a lawsuit will be filed against the alleged violators unless they agree to "provide clear and reasonable warnings" to consumers or "reformulate such products to eliminate the BPS exposures."
The retailers will also have to pay an "appropriate civil penalty."
The organization advised consumers to decline paper receipts whenever possible.
Click Here To Sign Up For Our Health Newsletter
"Store workers who must handle receipts should wear gloves if possible or avoid using alcohol-based hand cleaners before handling a receipt, because it can significantly increase the absorption of BPS," said CEH Senior Director Shakoora Azimi-Gaylon in the release.
"Receipts are made from thermal paper, which shouldn't be recycled because they contain bisphenols like BPA and BPS, which can contaminate the recycling stream and pose health and environmental risks."
Fox News senior medical analyst Dr. Marc Siegel noted that digital receipts are more prevalent than ever.
"We are definitely moving in the direction of digital receipts anyway," the medical expert told Fox News Digital.
Siegel also noted that many Americans are exposed to Bisphenol A (BPA) without noticing it – for example, it can commonly be found on smartphone cases, despite not being found on iPhones.
For more Health articles, visit www.foxnews.com/health.
More research needs to be done on the impact of "forever chemicals" like BPS, the doctor suggested.
"Forever chemicals are everywhere and there is a concern about fertility," Siegel cautioned.
"We need to do a better job of documenting and limiting exposure."
BPS has been scrutinized in recent years over its potential to adversely impact people's health.
In 2021, German researchers found that the chemical compound could "seriously damage" human brains after studying its effects on the nerve cells of goldfish.Original article source: Holding paper receipts for just 10 seconds can pose health risks, researchers warn
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Upsize LLC Opens New Male Enhancement Clinic in Dallas, Offering Revolutionary Non-Surgical Procedures
Upsize LLC Opens New Male Enhancement Clinic in Dallas, Offering Revolutionary Non-Surgical Procedures

Business Upturn

timean hour ago

  • Business Upturn

Upsize LLC Opens New Male Enhancement Clinic in Dallas, Offering Revolutionary Non-Surgical Procedures

DALLAS, July 24, 2025 (GLOBE NEWSWIRE) — Upsize Clinic, a leading provider of non-surgical male enhancement treatments, announces the opening of its newest clinic location in Dallas at 5232 Forest Lane, Suite 170. The clinic, led by board-certified physician Dr. Brad Sellers, offers the company's proprietary Upsize™ and Firm-X™ procedures, providing men in the Dallas-Fort Worth metroplex access to clinically proven, minimally invasive male enhancement procedures. The new Dallas location represents Upsize's continued national expansion, following the company's recent milestone of surpassing 1,500 successful procedures across its network of 20 affiliated physicians nationwide. The clinic specializes in two groundbreaking treatments: the Upsize™ procedure utilizing hyaluronic acid dermal fillers for girth enhancement, and the Firm-X™ treatment employing neuromodulator injections for improved function and appearance. 'Dallas men now have access to safe, effective enhancement options that deliver immediate results without the risks and downtime associated with surgical procedures,' said Dr. Brad Sellers, Medical Director of Upsize Dallas. 'These innovative treatments represent a significant advancement in male aesthetic medicine, offering natural-looking results that boost confidence and improve quality of life.' About Dr. Brad Sellers Dr. Sellers brings over two decades of medical expertise to his practice, having served as Medical Director and Associate Medical Director at several prominent Dallas-area Emergency Departments and Level 1 and Level 2 Trauma Centers. His extensive background in emergency medicine, combined with his Certified Physician Executive credentials from the American Association of Physician Leaders, ensures the highest standards of patient safety and care. Recently completing specialized training in male enhancement procedures through Upsize LLC, as well as neurotoxin and dermal filler certification from the National Laser Institute, Dr. Sellers has expanded his practice to focus on intimate wellness and aesthetic treatments for men. His commitment to excellence and patient-centered approach makes him uniquely qualified to deliver these innovative procedures. The Upsize™ Procedure: Non-Surgical Girth Enhancement The flagship Upsize™ procedure uses FDA-approved hyaluronic acid dermal fillers (used off-label) administered via micro-cannula to achieve natural girth enlargement and improved symmetry. Key benefits include: Immediate Results : Patients see enhancement immediately following the 30-minute in-office procedure : Patients see enhancement immediately following the 30-minute in-office procedure Minimal Downtime : Most men return to normal activities within days : Most men return to normal activities within days Reversible Option : Results can be adjusted or reversed if desired : Results can be adjusted or reversed if desired Natural Feel : Maintains natural texture and sensation : Maintains natural texture and sensation Long-Lasting: Results typically last an average of 24 months Firm-X™: Revolutionary Neuromodulator Treatment The innovative Firm-X™ treatment utilizes neurotoxin injections to enhance male sexual health and appearance. This procedure works by relaxing smooth muscles in corpus cavernosum vasculature, leading to: Enhanced blood flow and circulation Reduced retraction for a fuller appearance Improvements in erectile dysfunction The treatment involves strategic placement of 100 units of neuromodulator through four injection points, with the entire procedure completed in under 30 minutes. Meeting Growing Demand for Male Enhancement The opening of Upsize Dallas addresses increasing demand for physician administered male aesthetic treatments in North Texas. As men become more comfortable seeking enhancement options, the need for safe, effective alternatives to risky surgeries and unregulated products has grown significantly. 'Men seeking enhancement deserve access to clinically proven treatments performed by qualified medical doctors,' Dr. Sellers noted. 'Our procedures offer a discreet, professional solution that prioritizes both results and safety.' Comprehensive Patient Care The Dallas clinic provides confidential consultations where patients can discuss their options and determine the most appropriate treatment plan. Both procedures are performed in a discrete, medical-grade facility with strict adherence to safety protocols. Patients receive lifetime follow-up care at no additional charge, ensuring ongoing support and satisfaction. About Upsize LLC Headquartered in Roseville, California, Upsize LLC specializes in minimally invasive male enhancement treatments. The company's proprietary procedures have earned recognition for their safety profile, immediate results, and high patient satisfaction rates. With locations across California, Texas, Florida, New York, New Jersey, Ohio, Arizona, Nebraska, and international expansion into Panama and Canada, Upsize continues to lead innovation in male aesthetic medicine. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

CDx Diagnostics Receives FDA Breakthrough Device Designation for Its WATS3D Test System for Esophageal Cancer
CDx Diagnostics Receives FDA Breakthrough Device Designation for Its WATS3D Test System for Esophageal Cancer

Associated Press

timean hour ago

  • Associated Press

CDx Diagnostics Receives FDA Breakthrough Device Designation for Its WATS3D Test System for Esophageal Cancer

Novel AI-powered laboratory test for diagnosis of Barrett's esophagus, with or without dysplasia SUFFERN, NEW YORK / ACCESS Newswire / July 24, 2025 / CDx Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its proprietary WATS3D diagnostic system, a 'first-of-a-kind' AI-powered digital pathology system using wide area transepithelial sampling for the diagnosis of Barrett's esophagus and early neoplastic alterations in patients at risk for disease progression. 'The Breakthrough Device Designation recognizes what the volume of clinical data has shown: the WATS3D Test improves the ability to detect dysplasia in Barrett's esophagus, offering patients and physicians an improved method of detection of patients at risk of development of esophageal cancer,' said Robert Odze, MD, a leading gastrointestinal pathologist. To meet the requirements for FDA Breakthrough Device Designation, CDx Diagnostics submitted technical and clinical evidence from large multi-center studies showing that the WATS3D Test is 'more effective' than the Seattle biopsy protocol for the diagnosis of Barrett's esophagus, dysplasia and esophageal cancer. 'With data from greater than 23,000 patients, the WATS3D Test continues to demonstrate its potential to detect early-stage neoplastic disease that might be missed with conventional biopsies,' said Karen Hoffman, MD, Director of R&D at CDx Diagnostics. 'This designation recognizes the science behind our platform and supports our ongoing efforts to improve early detection of patients at risk.' The WATS3D Test System leverages proprietary artificial intelligence (AI) enabled algorithm for analysis of high-resolution digital pathology using novel 3-dimensional images from specimens collected using the WATS3D brush to identify precancerous and cancerous cells and assess the risk of progression to cancer. The WATS3D System was developed by CDx Diagnostics and is performed in the company's CLIA-certified, CAP accredited, New York state licensed clinical laboratory in Suffern, NY. For more information, visit or contact us at [email protected]. About CDx Diagnostics CDx Diagnostics' mission is to Empower Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time. CDx Diagnostics is changing the landscape of cancer prevention and diagnosis through innovative AI-driven digital pathology solutions developed and performed in the company's CLIA-certified, CAP accredited clinical laboratory in Suffern, New York. The company's first advanced diagnostic test- the WATS3D Test system powered by the WATS3D Esophageal AI Algorithm - has FDA Breakthrough Device Designation for the diagnosis of Barrett's esophagus (BE), with and without dysplasia. About the WATS3D Test System The WATS3D Test system is an AI-powered digital pathology test system that helps prevent the progression of neoplasia via more effective identification of Barrett's esophagus (BE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and esophageal adenocarcinoma (EAC). Developed and performed by CDx Diagnostics, the WATS3D Test leverages artificial intelligence (AI) enabled analysis using the WATS3D Esophageal AI Algorithm and 3D digital imaging of samples collected using a WATS3D brush to identify precancerous and cancerous cells and evaluate the risk of progression to cancer. The WATS3D Test has been used to analyze over 400,000 patient samples to identify those requiring earlier intervention, reduce time to treatment, and improve patient outcomes. Contact Information William Standwill Marketing [email protected] 845-777-7000 SOURCE: CDx Diagnostics press release

LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.

Business Upturn

time2 hours ago

  • Business Upturn

LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.

By Business Wire India Published on July 24, 2025, 21:59 IST Business Wire India ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S. 1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease. 2,3 The approval represents an important milestone for LEO Pharma's expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs. LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.1 ANZUPGO is an innovative steroid-free, topical pan-Janus kinase (JAK) inhibitor for adults with CHE.1 ANZUPGO inhibits the JAK-STAT pathway, specifically blocking the activity of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), and suppresses the various inflammatory responses that play a key role in the onset and subsequent flares of CHE.1,2,4 The FDA approval of ANZUPGO marks a significant milestone in LEO Pharma's strategy to expand its presence in the U.S. market and deliver purposeful innovation in skin health. In preparation for bringing ANZUPGO to the U.S. patients, LEO Pharma has significantly upscaled its operations across key functions – including a 50% increase in the sales force. 'ANZUPGOis a good example of how we transform a real need in the market into medicines that can help make a difference for people living with serious skin diseases such as CHE,' said Christophe Bourdon, CEO, LEO Pharma. 'After successfully launching ANZUPGOin several countries, we're proud to now bring this innovation to adult patients with moderate-to-severe CHE in the United States. The approval of ANZUPGO reinforces our commitment to investing in difficult-to-treat skin conditions to deliver new treatments to patients where the need is greatest. We're truly grateful to the patients and physicians who participated in our studies and helped make this approval possible.' CHE is a highly debilitating inflammatory skin disease that affects approximately one in ten adults worldwide, causing itchy, painful, blistered, or swollen skin that can interfere with daily activities.2,3,5,6 The FDA approval of ANZUPGO provides adults in the U.S. living with moderate-to-severe CHE with the first and only treatment option specifically approved for this skin disease, just as it will be the first and only topical pan-JAK-inhibitor on the U.S. market. 'Chronic hand eczema can be a very difficult disease for adults to manage, especially given the lack of treatment options in the U.S. until now,' said Robert Spurr, EVP and President, North America, LEO Pharma. 'As the first and only FDA-approved treatment specifically for CHE in the U.S., ANZUPGO further establishes our company's real commitment to bringing treatments to market that address unmet needs in medical dermatology.' The FDA approval is the latest regulatory milestone for ANZUPGO, following the European Commission (EC) approval in 2024 and several launches internationally, including Germany, Switzerland, the United Kingdom and the United Arab Emirates. *Ends* About ANZUPGO®(delgocitinib) Cream ANZUPGO® (delgocitinib) cream is currently FDA approved in the U.S. as the first and only treatment for chronic hand eczema (CHE). ANZUPGO is also approved in the European Union, United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or not advisable. ANZUPGO cream is also under investigation in other markets. Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended by the U.S. FDA.1 ANZUPGO cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.7 In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. The full U.S. FDA Prescribing Information and Medication Guide are available here: About Chronic Hand Eczema Chronic hand eczema (CHE) is defined as hand eczema (HE) that lasts for three or more months or relapses twice or more within a year.5,8 HE is one of the most common skin disorders of the hands and in a substantial number of patients, it can develop into a chronic condition.9 CHE affects approximately one in ten adults worldwide.2,3 It is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.6 The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome.2 CHE has been shown to cause psychological and functional burdens that impact patient quality of life,10,11 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities.12 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.13 About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit References ANZUPGO® (delgocitinib) cream. Prescribing Information. FDA. July 2025. Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. Quaade AS, Simonsen AB, Halling A-S, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population – A systematic review and meta-analysis. Contact Dermatitis. 2021;84:361–374. Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64:41-51. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233. Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1-e22. Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24 Suppl 3:1-20. Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991. Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168. Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626. MAT-84121 July 2025 View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store